Search - tctmd.com

Displaying 1 - 9 of 9

Sort: Relevancy | Date

News Industry News

Bristol-Myers Squibb and Pfizer Enroll First Patient in Phase 4 AUGUSTUS Trial to Evaluate Safety of Eliquis (apixaban) in Nonvalvular Atrial Fibrillation Patients with a Recent ACS or Undrgoing PCI

September 09, 2015

News Industry News

The Medicines Company Receives Market Authorization Renewal for Angiox® (Bivalirudin) from the European Medicines Agency and the European Commission

July 07, 2014

News Industry News

Study Find Pre-Hospital Administration of Bivalirudin Substantially Improves Outcomes Compared to Heparin in Heart Attack Patients

October 30, 2013

News Industry News

Accumetrics Obtains CE Mark for Therapeutic Window Claim on the VerifyNow P2Y12 Test

April 16, 2013

News Industry News

8500+ Patient Trial Validates Association between High Platelet Reactivity and 1-Year Cardiovascular Outcomes at TCT 2012

October 25, 2012

News Industry News

Study Finds That Prasugrel May Reduce Cardiovascular Events Among Patients Managed Medically After an Angiogram for Acute Coronary Syndrome

October 24, 2012

News Industry News

Low CV Event Rate Prompts Closure of Prasugrel Trial

November 09, 2011

News Industry News

Scripps Health and The Medicines Company Announce Late Breaking BRIDGE Trial Results Presented at TCT

November 08, 2011

News Industry News

2011 Surgical Guidelines Recommend Point-of-Care Platelet Reactivity Testing Prior to Surgery

March 08, 2011

Advertisement

Bristol-Myers Squibb and Pfizer Enroll First Patient in Phase 4 AUGUSTUS Trial to Evaluate Safety of Eliquis (apixaban) in Nonvalvular Atrial Fibrillation Patients with a Recent ACS or Undrgoing PCI

The Medicines Company Receives Market Authorization Renewal for Angiox® (Bivalirudin) from the European Medicines Agency and the European Commission

Study Find Pre-Hospital Administration of Bivalirudin Substantially Improves Outcomes Compared to Heparin in Heart Attack Patients

Accumetrics Obtains CE Mark for Therapeutic Window Claim on the VerifyNow P2Y12 Test

8500+ Patient Trial Validates Association between High Platelet Reactivity and 1-Year Cardiovascular Outcomes at TCT 2012

Study Finds That Prasugrel May Reduce Cardiovascular Events Among Patients Managed Medically After an Angiogram for Acute Coronary Syndrome

Low CV Event Rate Prompts Closure of Prasugrel Trial

Scripps Health and The Medicines Company Announce Late Breaking BRIDGE Trial Results Presented at TCT

2011 Surgical Guidelines Recommend Point-of-Care Platelet Reactivity Testing Prior to Surgery

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content